# Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer

> **NCT00662129** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel albumin-stabilized nanoparticle formulation

## Key facts

- **NCT ID:** NCT00662129
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-08
- **Final completion:** 2013-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662129, "Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00662129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*